Latest News and Press Releases

OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and...

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...

Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...

Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...

Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...

Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...

Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...

Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...